-
公开(公告)号：US20190062383A1
公开(公告)日：2019-02-28
申请号：US16124295
申请日：2018-09-07
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Wilson Edwards , Chichi Huang , Wai-Ping Leung , Ronald Swanson , Alan Wickenden
IPC: C07K14/435 , C07K14/765
Abstract: The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.
-
公开(公告)号：US10155809B2
公开(公告)日：2018-12-18
申请号：US15707317
申请日：2017-09-18
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
Abstract: Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFNα and IFNω.
-
公开(公告)号：US20140234304A1
公开(公告)日：2014-08-21
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos ALMAGRO , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US20190135912A1
公开(公告)日：2019-05-09
申请号：US16184270
申请日：2018-11-08
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
IPC: C07K16/24
Abstract: Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are usefule in the treatment of diseases associated with increased production of IFNα and IFNω.
-
公开(公告)号：US20190106489A1
公开(公告)日：2019-04-11
申请号：US16222285
申请日：2018-12-17
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
CPC classification number: C07K16/249 , A61K38/13 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
Patent Agency Ranking
公开(公告)号：US08951525B2
公开(公告)日：2015-02-10
申请号：US13803887
申请日：2013-03-14
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: A61K39/395 , C07K16/46 , C07K16/36 , C07K16/28 , A61K39/00
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
-
公开(公告)号：US10759854B2
公开(公告)日：2020-09-01
申请号：US16424907
申请日：2019-05-29
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Judith Connor , Chichi Huang , Jarrat Jordan , Xiefan Lin-Schmidt , Jinquan Luo , Lu Lu , Christian Martinez , Galina Obmolova , Ronald Swanson
IPC: C07K16/24 , A61K38/13 , A61K45/06 , A61K39/395 , A61K39/00
Abstract: The present invention relates to antibodies that broady neutralize interferon-α and interferon-ω, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US10179808B2
公开(公告)日：2019-01-15
申请号：US14163158
申请日：2014-01-24
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Wilson Edwards , Chichi Huang , Wai-Ping Leung , Ronald Swanson , Alan Wickenden
IPC: C07K14/435 , C07K14/765
Abstract: The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.
-
公开(公告)号：US08999333B2
公开(公告)日：2015-04-07
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US20140255401A1
公开(公告)日：2014-09-11
申请号：US14163158
申请日：2014-01-24
Applicant: Janssen Biotech, Inc.
Inventor： Ellen Chi , Wilson Edwards , Chichi Huang , Wai-Ping Leung , Ronald Swanson , Alan Wickenden
IPC: C07K14/435 , C07K14/765
CPC classification number: C07K14/43522 , C07K14/765 , C07K2319/30 , C07K2319/31
Abstract: The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing.
Abstract translation: 本发明涉及Kv1.3拮抗剂和编码它们的多核苷酸，以及制备和使用上述物质的方法。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.02 seconds)
